Arjona Ferreira Juan Camilo's Form 4 filing
Myovant Sciences Ltd. (MYOV) · filed Sep 29, 2021
- Accession no.
- 0001209191-21-058051
- Filed
- Sep 29, 2021
- Trade date
- Sep 27, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $170.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Arjona Ferreira Juan CamiloCIK 0001714080 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 27, 2021 | Common Shares | MOption exerciseAcquired | +7,000 | $7.78 | +$54,460 | 178,329 | Direct | |
| Sep 27, 2021 | Common Shares | SSaleDisposed | −7,000 | $24.32F2 | −$170,240 | 171,329 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 27, 2021 | Common Shares | MOption exerciseDisposed | −7,000 | $0.00 | $0 | 159,100 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The shares were sold at prices ranging from $24.01 to $24.96. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.